Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2014 08:03 ET | Source: Active Biotech

Change in the clinical development program for laquinimod

LUND, Sweden, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that its partner Teva Pharmaceuticals (NYSE: TEVA), has decided not to proceed to the...
February 19, 2014 08:00 ET | Source: Active Biotech

Ändring i det kliniska utvecklingsprogrammet för laquinimod

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 19 februari, 2014 - Active Biotech...
February 19, 2014 08:00 ET | Source: Active Biotech

Change in the clinical development program for laquinimod

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, February 19, 2014 - Active...
February 13, 2014 02:37 ET | Source: Active Biotech

Active Biotech AB Year-end report January - December 2013

LUND, Sweden, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Laquinimod Teva remains committed to the development of laquinimod (NERVENTRA®) for the treatment of multiple sclerosis (MS) On...
February 13, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Year-end report January - December 2013

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod Teva remains committed to the...
February 13, 2014 02:30 ET | Source: Active Biotech

Active Biotech AB Bokslutsrapport januari - december 2013

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod Teva fortsätter att med...
January 27, 2014 00:42 ET | Source: Active Biotech

Teva and Active Biotech Remain Committed to the Development of NERVENTRA(r) (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA's CHMP

LUND, Sweden, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the...
January 24, 2014 07:13 ET | Source: Active Biotech

Teva och Active Biotech fortsätter att med full kraft driva utvecklingen av NERVENTRA® (laquinimod) för behandling av multipel skleros efter negativ bedömning från EMA:s CHMP

JERUSALEM, Israel & LUND, Sverige, den 24 januari, 2014 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) och Active Biotech (NASDAQ OMX NORDIC: ACTI) meddelar idag att de fortsätter att med...
January 24, 2014 07:13 ET | Source: Active Biotech

Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA's CHMP

JERUSALEM, Israel & LUND, Sweden, January 24, 2014 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain...
January 09, 2014 05:25 ET | Source: Active Biotech

Active Biotech to Present at the 32nd Annual J.P. Morgan Healthcare Conference

LUND, Sweden, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference held January 13-16, 2014 in San...